Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology
Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology -- Early data from ongoing PROTECT trial suggest stable and durable response to KRYSTEXXA (pegloticase injection) therapy in treating uncontrolled gout among people with kidney transplants -- -- Data on the company's investigational compound (HZN-4920) under evaluation for rheumatoid arthritis will be presented during an oral session on June 3 at 10:15 a.m. CEST -- Horizon Therapeutics plc (Nasdaq: HZNP) today presented new data during the EULAR European Congress of Rheumatology from the o...
Source: finanznachrichten.de